Drugs to treat rare disorders and genetic diseases are particularly demanding to develop, and biotechnology companies predominantly have been the firms that have stepped up to that challenge.

COLLEGE PARK, Md. - Federal advisers Thursday said Arpida AG failed to show in clinical trials that its experimental antibiotic iclaprim was safe and effective for treating patients with complicated skin and skin structure infections (cSSSIs). (BioWorld Today)